Abbonarsi

Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations - 16/08/20

Doi : 10.1016/j.ahj.2020.04.028 
Nancy Luo, MD a, , Bradley G. Hammill, DrPH b, c, Adam D. DeVore, MD, MHS b, c, Haolin Xu, MS b, Gregg C. Fonarow, MD d, Nancy M. Albert, PhD e, Roland A. Matsouaka, PhD b, Adrian F. Hernandez, MD, MHS b, c, Clyde Yancy, MD f, Robert J. Mentz, MD b, c
a Dignity Health Heart and Vascular Institute, Sacramento, CA 
b Duke Clinical Research Institute, Durham, NC 
c Department of Medicine, Duke University School of Medicine, Durham, NC 
d Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, CA 
e Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH 
f Northwestern University Feinberg School of Medicine, Chicago, IL 

Reprint requests: Nancy Luo, MD, FACC, Dignity Health Heart and Vascular Institute, Greater Sacramento Region, 3939 J Street Suite 230, Sacramento, CA 95819.Dignity Health Heart and Vascular InstituteGreater Sacramento Region, 3939 J Street Suite 230SacramentoCA95819

Background

Little is known about the impact of accountable care organizations (ACO) on hospitalized heart failure (HF) patients, a high-cost and high-risk population.

Objective

We linked Medicare fee-for-service claims from 2013 to 2015 with data from American Heart Association Get With The Guidelines–HF registry to compare HF care, post-discharge outcomes, and total annual Medicare spending by ACO status at discharge.

Methods

Using adjusted Cox models and accounting for competing risks of death, we compared all-cause mortality and readmission at 1 year by ACO status with reporting of hazard ratios (HR) and 99% confidence intervals (CI).

Results

The study included 45,259 HF patients from 300 hospitals, with 21.1% assigned to an ACO. Patient characteristics were similar between the two groups with a few exceptions. The ACO patients lived in geographic areas with higher median income ($54400 [IQR $48600-65900] vs $52300 [$45900-61200], P < .0001). Compliance with four HF-specific quality measures was modestly higher in the ACO group (80% vs 76%, P < .0001). In adjusted analysis, ACO status was associated with similar all-cause readmission (HR: 1.03; 99% CI: 0.99, 1.07) but lower risk of 1-year mortality (HR: 0.85; 99% CI: 0.85, 0.90) compared with non-ACO status. Median Medicare spending in the calendar year of hospitalization was similar (ACO $42,737 [IQR $23,011-72,667] vs non-ACO $42,586 [$22,896-72,518], P = 0.06).

Conclusions

Among Medicare patients hospitalized for HF, participation in an ACO was associated with similar rates of all-cause readmission and no associated cost reductions compared with non-ACO status. There was a lower risk of 1-year mortality associated with ACO participation, which warrants further evaluation.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Khadijah Breathett, MD, MS, served as guest editor for this article.
 Disclosures:
NL: Consulting AstraZeneca
ADD: Research funding from AstraZeneca, Amgen, the American Heart Association, Bayer, Luitpold Pharmaceuticals, the NHLBI, PCORI and Novartis; Consulting with AstraZeneca, LivaNova, Mardil Medical, Novartis and Procyrion.
GCF: Consulting Abbott, Amgen, Bayer, Janssen, Medtronic, Novartis
AFH: Research funding from American Regent, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck, Novartis, Verily; Consulting with AstraZeneca, Bayer, Boehringer-Ingelheim, Boston Scientific, Merck and Novartis
All other authors report no significant disclosures.


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 226

P. 13-23 - Agosto 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines
  • Alexander C. Fanaroff, Marat Fudim, Robert M. Califf, Stephan Windecker, Sidney C. Smith, Renato D. Lopes
| Articolo seguente Articolo seguente
  • Population-level surveillance of congenital heart defects among adolescents and adults in Colorado: Implications of record linkage
  • Tessa L. Crume, Lindsey M. Duca, Toan Ong, Emily Kraus, Ken Scott, Amber Khanna, David Kao, Christopher M. Rausch, Lisa McKenzie, Matthew F. Daley, Suzanne Coleman, Michael G. Kahn, Everett Costa, Arthur J. Davidson

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.